| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 262,506 | |||
| General and administrative | 52,763 | |||
| Total operating expenses | 315,269 | |||
| Loss from operations | -315,269 | |||
| Interest income | 22,083 | |||
| Interest expense | 11,428 | |||
| Change in fair value of warrant liabilities and contingent earn-out shares | -592 | |||
| Other income (expense), net | 0 | |||
| Total non-operating income, net | 10,063 | |||
| Loss before income taxes | -305,206 | |||
| Net loss | -305,206 | |||
| Unrealized gain on investments, net | 1,814 | |||
| Comprehensive loss | -303,392 | |||
| Net loss per share attributable to common stockholders, basic | -1.61 | |||
| Net loss per share attributable to common stockholders, diluted | -1.61 | |||
| Weighted average number of shares outstanding, diluted | 189,231,562 | |||
| Weighted-average shares used to compute net loss per share attributable to common stockholders-basic | 189,231,562 | |||
Revolution Medicines, Inc. (RVMDW)
Revolution Medicines, Inc. (RVMDW)